Fractyl Health Stock Forum

$Fractyl Health (GUTS.US)$
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
Friday, 31st January at 8:01 am
Prioritizing Revita's clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 2025 a...

$Fractyl Health (GUTS.US)$
stay away from this app alert

$Fractyl Health (GUTS.US)$
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
Monday, 13th January at 7:00 am
Company also announces strong enrollment progress for REMAIN-1 weight maintenance pivotal study
High demand from patients and physicians indicates significant interest in REMAIN-1 study and GLP-1 discontinuation; mid-point analysis on-track and anticipa...

$Fractyl Health (GUTS.US)$
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Thursday, 12th December at 7:00 am
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose
Results confirm ability to directly target pancreas with novel delivery catheter and rout...

$Fractyl Health (GUTS.US)$ BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease...

$Fractyl Health (GUTS.US)$ Fractyl Health: Results Show Sustained Maintenance of Weight Loss, Blood Sugar Levels at Week 13 in Dio Mice Given Rjva-001 & Continuing High Fat Diet

$Fractyl Health (GUTS.US)$
Oral Presentation
Title: Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves Metabolism in Obese Mice
Presentation Date & Time: Tuesday, November 5, 2024, 10:45 am - 11:00 am (CDT)
Location: Henry B. Gonzalez Convention Center, Room 007
Poster Presentation
Title: Duodenal Mucosal Resurfacing Durably Maintains Weight Loss in Metabolic Disease
Presentation Date & Time: Sunday, November 3, 2024,...

$Fractyl Health (GUTS.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$ $Oklo Inc (OKLO.US)$ $Revance Therapeutics(Delisted) (RVNC.US)$ $PROCEPT BioRobotics (PRCT.US)$ $Atlas Lithium (ATLX.US)$ $EyePoint Pharmaceuticals (EYPT.US)$ $Porch Group (PRCH.US)$ $Top Wealth Group Holding (TWG.US)$ $Global Mofy AI (GMM.US)$ $Monte Rosa Therapeutics (GLUE.US)$ $Evoke Pharma (EVOK.US)$ $Greenlane (GNLN.US)$ $Autonomix Medical (AMIX.US)$ $Healthcare Triangle (HCTI.US)$
📊⚡️📊

$Fractyl Health (GUTS.US)$ Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
2 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that it will present compelling weight maintena...

$S&W Seed (SANW.US)$ $Fractyl Health (GUTS.US)$ $Volcon (VLCN.US)$ $Eterna Therapeutics (ERNA.US)$ $Lazydays (GORV.US)$ $Adagio Medical (ADGM.US)$ $EXCELFIN ACQUISITION CORP (XFIN.US)$ $Treasure Global (TGL.US)$ $HWH International (HWH.US)$ $iCoreConnect (ICCT.US)$
📊⚡️📊